Interesting Article From Kalkin & Media dated November 29th 2021. The article is tagged
" 3 Canadian COVID stocks to buy amid Omicron’s emergence"
it is comforting to know that at least SQI is starting to get some sort of recognition and exposure as suggested in the article.
"So, let us discuss three Canadian stocks that can see substantial growth amid the new COVID variant’s emergence."
Also nice to see that SQI is sandwiched between two other Canadian companies whose share price is much higher and perhaps is where SQI's SP should really be at. Could this be a sign of good things to come.
What puzzles me though is the statement made in the second paragraph when the article talks about SQI.
"SQI’s RALI-Dx™ IL-6 Severity Triage Test is said to help in identifying patients who are suffering severely from inflammation due to COVID-19 and other causes. This test got an FDA approval under non-EUA regulatory framework earlier this year in July."
Did I miss a news release about the FDA approving the RALI-Dx IL-6 Severity Triage Test.
Did the RALI-Dx IL -6 get FDA approval for the Severity Triage Test?
Thank you in advance if anyone can confirm this for me !!
https://kalkinemedia.com/ca/amp/stocks/healthcare/3-canadian-covid-stocks-to-buy-amid-omicrons-emergence